Pancreatic Cancer Research

ResearcherBrown UniversityActive in the last 2 years

Alexander Grenander Raufi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5645-2629; OpenAlex author ID A5050792634. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 11

  1. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  2. Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
  3. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  4. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-025-02345-5↗
  5. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX. Co-author DOI 10.1093/oncolo/oyad315↗
  6. Smoking is Not Associated with Lung Metastasis in Pancreatic Cancer. Co-author DOI 10.1080/07357907.2023.2203747↗
  7. Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.12.24.573257↗
  8. Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer. Co-author DOI 10.3390/ijms24044238↗
  9. Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fphar.2021.751568↗
  10. Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295). Co-author DOI 10.1097/coc.0000000000000762↗
  11. Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1053/j.seminoncol.2018.12.002↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael S. May · 7 shared papers, 2023–2026 · strength 1.42
  2. Gulam Abbas Manji · 7 shared papers, 2019–2026 · strength 1.32
  3. Jacob K.R. Jamison · 3 shared papers, 2023–2025 · strength 0.62
  4. Benjamin Izar · 3 shared papers, 2025–2026 · strength 0.57
  5. Alina Cornelia Iuga · 3 shared papers, 2023–2026 · strength 0.56
  6. Kenneth P. Olive · 3 shared papers, 2023–2026 · strength 0.56
  7. Susan Elaine Bates · 3 shared papers, 2019–2026 · strength 0.53
  8. John A. Chabot · 3 shared papers, 2019–2026 · strength 0.51
  9. Linda Y. Wu · 2 shared papers, 2026 · strength 0.39
  10. Michael D. Kluger · 2 shared papers, 2025–2026 · strength 0.37
  11. Wafik S. El‐Deiry · 2 shared papers, 2021–2023 · strength 0.36
  12. Attila A. Seyhan · 2 shared papers, 2021–2023 · strength 0.36
  13. Howard P. Safran · 2 shared papers, 2020–2026 · strength 0.30
  14. Lyndon Luk · 1 shared paper, 2024 · strength 0.24
  15. Alfred I. Neugut · 1 shared paper, 2023 · strength 0.20
  16. Emanuel F. Petricoin · 1 shared paper, 2026 · strength 0.20
  17. Brian William Labadie · 1 shared paper, 2026 · strength 0.20
  18. Andrea Califano · 1 shared paper, 2026 · strength 0.20
  19. Urszula N. Wasko · 1 shared paper, 2026 · strength 0.20
  20. Steven Francis Powell · 1 shared paper, 2025 · strength 0.19
  21. Benedito A. Carneiro · 1 shared paper, 2025 · strength 0.19
  22. Marisol Huerta · 1 shared paper, 2025 · strength 0.19
  23. Ludimila L. Cavalcante · 1 shared paper, 2025 · strength 0.19
  24. Andrès M.R. Cervantes · 1 shared paper, 2025 · strength 0.19
  25. Devalingam Mahalingam · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.